CSIMarket
 


Alkermes Plc   (ALKS)
Other Ticker:  
 
 

ALKS's Capital Expenditures Growth by Quarter and Year

Alkermes Plc 's Capital Expenditures results by quarter and year




ALKS Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 10.03 8.66 5.44
III Quarter September 14.45 10.47 4.81 6.41
II Quarter June 9.71 9.96 6.56 10.57
I Quarter March 6.86 7.79 7.99 19.80
FY   31.02 38.25 28.02 42.22



ALKS Capital Expenditures third quarter 2023 Y/Y Growth Comment
Alkermes Plc achieved in the third quarter 2023, above Company average Capital Expenditures growth of 38.04% year on year, to $ 14.45 millions.

According to the results reported in the third quarter 2023, Alkermes Plc achieved the best Capital Expenditures growth in Major Pharmaceutical Preparations industry. While Alkermes Plc ' s Capital Expenditures rise of 38.04% ranks overall at the positon no. 67 in the third quarter 2023.




ALKS Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - 15.82 % 59.19 % -82.98 %
III Quarter September 38.04 % 117.67 % -24.96 % -67.01 %
II Quarter June -2.51 % 51.83 % -37.94 % -33.52 %
I Quarter March -11.94 % -2.5 % -59.65 % -16.24 %
FY   - 36.51 % -33.63 % -53.57 %

Financial Statements
Alkermes Plc 's third quarter 2023 Capital Expenditures $ 14.45 millions ALKS's Income Statement
Alkermes Plc 's third quarter 2022 Capital Expenditures $ 10.47 millions Quarterly ALKS's Income Statement
New: More ALKS's historic Capital Expenditures Growth >>


ALKS Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - -4.2 % 80.04 % -15.13 %
III Quarter September 48.85 % 5.12 % -26.68 % -39.36 %
II Quarter June 41.55 % 27.86 % -17.9 % -46.62 %
I Quarter March -31.61 % -10.05 % 46.88 % -38.07 %
FY (Year on Year)   - 36.51 % -33.63 % -53.57 %




Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #0
Healthcare Sector #5
Overall #67

Capital Expenditures Y/Y Growth Statistics
High Average Low
169.07 % 20.68 % -67.72 %
(Sep 30 2017)   (Jun 30 2021)
Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #0
Healthcare Sector #5
Overall #67
Capital Expenditures Y/Y Growth Statistics
High Average Low
169.07 % 20.68 % -67.72 %
(Sep 30 2017)   (Jun 30 2021)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Alkermes Plc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
296.79 % 16.17 % -46.6 %
(Sep 30 2014)  


ALKS's III. Quarter Q/Q Capital Expenditures Comment
Alkermes Plc achieved in the III. Quarter 2023 above company average sequential Capital Expenditures jump of 48.85%, to $ 14.45 millions, from $9.71 millions in the second quarter.
Major Pharmaceutical Preparations company is undergoing a remarkable growth, not only reporting higher then regular increase, and additionally improving rate, Emma Persson, an industry contributor located in Stockholm added.

Within Major Pharmaceutical Preparations industry only one company achieved higher sequential Capital Expenditures growth. While Alkermes Plc 's Capital Expenditures growth quarter on quarter, overall rank is 27.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #2
Healthcare Sector #3
Overall #27
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #2
Healthcare Sector #3
Overall #27
Capital Expenditures Q/Q Growth Statistics
High Average Low
296.79 % 16.17 % -46.6 %
(Sep 30 2014)  


ALKS's III. Quarter Q/Q Capital Expenditures Comment
Alkermes Plc achieved in the III. Quarter 2023 above company average sequential Capital Expenditures jump of 48.85%, to $ 14.45 millions, from $9.71 millions in the second quarter.
ALKS is going from strength to strength, not only claiming higher then average increase, and also increasing pace.

Within Major Pharmaceutical Preparations industry only one company achieved higher sequential Capital Expenditures growth. While Alkermes Plc 's Capital Expenditures growth quarter on quarter, overall rank is 27.


Alkermes Plc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Capital Expenditures 12 Months Ending $ 41.05 $ 37.07 $ 37.32 $ 38.26 $ 36.89
Y / Y Capital Expenditures Growth (TTM) 11.27 % 18.7 % 34.14 % 36.53 % 48.75 %
Year on Year Capital Expenditures Growth Overall Ranking # 28 # 70 # 1511 # 1857 # 324
Seqeuential Capital Expenditures Change (TTM) 10.73 % -0.69 % -2.43 % 3.71 % 18.13 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 1018 # 80 # 1389 # 1168 # 214




Cumulative Capital Expenditures growth Comment
With the quarterly Capital Expenditures reported in the Sep 30 2023 period, Alkermes Plc 's cumulative twelve months Capital Expenditures were $ 41 millions, company would post below average annual Capital Expenditures growth of 18.13% year on year, if the fiscal year would end at Sep 30 2023.
A slow-down in the Alkermes Plc 's Capital Expenditures growth from the 9.71% growth in Jun 30 2023.

Looking into Healthcare sector trailing twelve month Capital Expenditures increase, only one company had higher growth. While Total ranking has impoved so far to 28, from total ranking in previous quarter at 70.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
169.07 %
20.68 %
-67.72 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 53
Healthcare Sector # 2
Overall # 28

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
169.07 %
20.68 %
-67.72 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 53
Sector # 140
S&P 500 # 1018
Cumulative Capital Expenditures growth Comment
With the quarterly Capital Expenditures reported in the Sep 30 2023 period, Alkermes Plc 's cumulative twelve months Capital Expenditures were $ 41 millions, company would post below average annual Capital Expenditures growth of -67.72% year on year, if the fiscal year would end at Sep 30 2023.
A slow-down in the Alkermes Plc 's Capital Expenditures growth from the 9.71% growth in Jun 30 2023.

Looking into Healthcare sector trailing twelve month Capital Expenditures increase, only one company had higher growth. While Total ranking has impoved so far to 28, from total ranking in previous quarter at 70.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
169.07 %
20.68 %
-67.72 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 53
Healthcare Sector # 2
Overall # 28

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
169.07 %
20.68 %
-67.72 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 53
Sector # 140
S&P 500 # 1018




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
ALKS's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for ALKS's Competitors
Capital Expenditures Growth for Alkermes Plc 's Suppliers
Capital Expenditures Growth for ALKS's Customers

You may also want to know
ALKS's Annual Growth Rates ALKS's Profitability Ratios ALKS's Asset Turnover Ratio ALKS's Dividend Growth
ALKS's Roe ALKS's Valuation Ratios ALKS's Financial Strength Ratios ALKS's Dividend Payout Ratio
ALKS's Roa ALKS's Inventory Turnover Ratio ALKS's Growth Rates ALKS's Dividend Comparisons



Companies with similar Capital Expenditures jump for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Sep 30 2023
West Pharmaceutical Services Inc 65.74%$ 65.744 millions
Schrodinger Inc 64.01%$ 64.009 millions
Veracyte inc 63.48%$ 63.477 millions
Radnet Inc 60.93%$ 60.932 millions
Moderna Inc 57.30%$ 57.303 millions
Eli Lilly And Company57.21%$ 57.210 millions
Agilon Health Inc 57.20%$ 57.201 millions
Vor Biopharma Inc 56.04%$ 56.040 millions
Lifevantage Corp55.85%$ 55.846 millions
Yunhong Green Cti Ltd 55.56%$ 55.556 millions
Amgen Inc 55.00%$ 55.000 millions
Vivos Therapeutics Inc 54.00%$ 54.000 millions
Beigene ltd 53.97%$ 53.969 millions
Hyperfine Inc 52.02%$ 52.023 millions
Intuitive Surgical Inc 51.57%$ 51.567 millions
Precision Optics Corporation Inc 49.16%$ 49.164 millions
Biogen Inc 48.22%$ 48.223 millions
Acorda Therapeutics Inc 46.67%$ 46.667 millions
Femasys Inc 46.54%$ 46.543 millions
Staar Surgical Company46.42%$ 46.421 millions
Livanova Plc44.31%$ 44.314 millions
Seres Therapeutics Inc 44.11%$ 44.106 millions
Abcellera Biologics Inc 43.95%$ 43.947 millions
Eyepoint Pharmaceuticals Inc 43.57%$ 43.573 millions
Irhythm Technologies Inc 43.49%$ 43.486 millions
Veru Inc 43.05%$ 43.054 millions
Integra Lifesciences Holdings Corp42.85%$ 42.851 millions
Bio techne Corp42.24%$ 42.235 millions
Msa Safety Incorporated41.45%$ 41.451 millions
Pluri Inc 41.10%$ 41.096 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com